PICOS component | PKU and MCAD deficiency | Other COMET paediatric projects |
---|---|---|
Population | (i) Children (aged 18Â years or younger) diagnosed with PKU or MCAD deficiency | Children (aged 18Â years or younger) diagnosed with a paediatric condition |
(ii) For publications focused on long-term follow-up initiatives for newborn screening programmes, children (aged 18Â years or younger) diagnosed with inherited metabolic diseases generally (including but not limited to PKU and MCAD deficiency) | ||
Exclusions: for (ii) above, publications describing long-term follow-up initiatives for newborn screening, we will exclude publications where neither PKU nor MCAD deficiency are encompassed within the set of diseases being studied | Â | |
Interventions/comparators/exposures | As the review’s objectives are to establish a listing of reported outcomes, no restrictions will be in place related to specific interventions or exposures | |
Outcomes | No restrictions will be in place in terms of outcomes, given the objectives of the review; mapping of reported outcomes will be established | |
Study design | (i) Eligibility will be restricted to non-animal studies of PKU and MCAD deficiency, using any study design | Eligibility will be restricted to publications describing findings from core outcome initiatives related to otherpaediatric conditions (nonspecific to PKU or MCAD) |
(ii) Publications focused on long-term follow-up initiatives related to newborn screening and IMD (which include PKU and/or MCAD deficiency within a larger group of diseases) | ||
Exclusions: case reports and case series with fewer than 5 subjects | ||
Language | English | English |